Arrowhead's Redemplo shows a stronger safety edge than Ionis' Tryngolza in new Phase 3 sHTG data, sharpening a fast-approaching triglyceride-drug rivalry.
MUNICH — Arrowhead is on course to crash Ionis Pharmaceuticals’ party.
Arrowhead’s RNA interference drug Redemplo looked safer as well as effective in two late-stage trials …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
ESC: AZ, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
A Novartis drug cut inflammation. Can it improve heart outcomes?
Arrowhead's Redemplo cut triglycerides 79%-81% in two Phase 3 trials for sHTG, boosting the company's shares by about 25%.
Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become t | Less than a month after Ionis…
To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive…
Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday.
The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.
Ionis wins FDA approval to expand Tryngolza into severe hypertriglyceridemia, a far larger market than its rare FCS launch, with…
